AMG 335 Expanded Access Program for IgG4-Related Disease
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Inebilizumab (Primary)
- Indications Autoimmune disorders
- Focus Expanded access; Therapeutic Use
- Sponsors Amgen
- 27 Sep 2024 New trial record